NEW YORK — Flow cytometry instrument developer Cytek Biosciences said on Thursday that it has raised $120 million in a Series D financing round.
The round was led by RA Capital and Hillhouse Capital with participation from OrbiMed and Lyfe Capital.
Cytek said that it will use the funding to expand its global infrastructure, as well as to expand its presence in the cell-analysis market in areas such as immunotherapy, immuno-oncology, and infectious disease.
In conjunction with the round, members of RA Capital and Hillhouse Capital have joined Cytek's board of directors.
In August, Cytek launched its cFluor line of reagents for its Aurora and Northern Lights cytometry systems. About a year ago, the Fremont, California-based company updated the Aurora instrument, which it said can run beyond 40-color panels.